ReviewExperimental and clinical psychopharmacology2025
A comprehensive review on oral nicotine pouches: Available scientific evidence and future research needs.
Review in Experimental and clinical psychopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Switching from Cigarettes to E-Cigarettes and Oral Nicotine Pouches in Adults with Low-Income Who Smoke: Qualitative Findings from a Pilot Randomized Controlled Trial.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2026Trial
- Oral Nicotine Pouches and the Emerging Addiction Crisis Among Youth in Pakistan: A Perspective.Health science reports · 2026Article
- Factors associated with considering switching to nicotine pouches among US adults who smoke.Drug and alcohol dependence reports · 2026Article
- The impact of question order on surveillance of nicotine pouch and smokeless tobacco use among adults in the United States.Preventive medicine reports · 2026Article
- Nicotine Pouch Use Among U.S. Adults in 2023 and 2024.American journal of preventive medicine · 2026Article
- An Investigation of Young Adults' Psychophysiological and Self-Report Responses to Paid Partnership Disclosures in Pro-Oral Nicotine Pouch Videos.American journal of preventive medicine · 2026Article
- Patterns of tobacco product use among US adults who use nicotine pouches and the association between nicotine pouch use and tobacco product use cessation.Tobacco control · 2026Article
- Oral nicotine pouches have arrived at U.S. college campuses.Journal of American college health : J of ACH · 2026Article
- Attractiveness and determinants of different tobacco products among Chinese smokers and non-smokers: a web-based cross-sectional study.Frontiers in public health · 2026Article
- Nicotine pouches: A wolf in sheep's clothing.Tobacco prevention & cessation · 2026Article
- Article
- 'Fuel your peak performance': marketing of nicotine pouches to athletes.Tobacco control · 2025Article
- Receiving coupons and discounts for nicotine pouches is associated with current use of nicotine pouches among United States adults: Results from the population assessment of tobacco and health (PATH) study wave 7 (2022-2023).Drug and alcohol dependence reports · 2025Article
- Smoking cessation message testing to inform app-based interventions for young adults - an online experiment.BMC public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Oral nicotine pouches (ONPs) are an emergent class of tobacco products that, unlike conventional oral smokeless tobacco products, contain a nicotine powder instead of tobacco leaves. This review synthesizes available data on ONPs in key research domains including survey studies, marketing/advertising studies, chemical characterization and in vitro studies, and clinical studies. Research findings relevant for ONP regulations are summarized, including who uses these products and why, how marketing tactics influence appeal and use intentions, what harmful and potentially harmful constituents they contain, and what acute effects they have on humans. Taken together, the current data suggest that ONPs likely produce less harm to individual users than conventional tobacco products (e.g., moist snuff, cigarettes) and can acutely suppress nicotine/tobacco withdrawal symptoms among current cigarette smokers. Thus, ONPs may be a viable harm reduction option for individuals who switch completely to using them from conventional products. However, randomized controlled trials are needed to determine if established tobacco users would use ONPs long term, and more independent academic research is needed given that most ONP studies to date are tobacco industry-funded. Additionally, ONPs have qualities (e.g., flavors, marketing claims of "tobacco free") that could increase appeal among youth and young adults, and these products can deliver nicotine at levels sufficient to cause dependence; widespread adoption of ONPs among otherwise nicotine-naive individuals may reduce their net public health benefit. This review concludes by suggesting future research directions necessary to increase scientific understanding of ONPs and inform regulations for these increasingly popular products. (PsycInfo Database Record (c) 2025 APA, all rights reserved).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.